We developed a unique technology platform called dual variable domain-immunoglobulin (DVD-Ig), which allows one drug to block two targets. This is in contrast to a typical monoclonal antibody (mAb), which has one unique binding domain with a single target to interrupt a disease process. A DVD-Ig, utilizing an immunoglobulin backbone, incorporates two pairs of distinct binding domains that can bind to two different targets independently. Simply, a DVD-Ig is capable of engaging two different molecules.[1]